EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
ROCKVILLE, Md., Oct. 31, 2013 - EntreMed, Inc. (ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced today the commencement of
a multi-center Phase 2 study entitled "Phase II Study of Oral
ENMD-2076 Administered to Patients with Ovarian Clear Cell
Carcinomas." The study is led by principal investigator Amit M. Oza,
MD at Princess Margaret Cancer Centre in Toronto, Canada with
participation of up to seven additional cancer centers in Canada and
the United States. More information about the clinical trial can be
found at www.clinicaltrials.gov.
Amit M. Oza, MD, principal investigator of the study, commented,
"Ovarian clear cell carcinomas (OCCC) account for approximately 5-13%
of all epithelial ovarian cancers and compared to other subtypes, are
associated with poorer prognosis and can be resistant to conventional
platinum-based chemotherapy. It presents a considerable clinical
challenge and there is a need to develop new therapeutics in the
management of this disease. ENMD-2076 has demonstrated single agent
activity in tumor models of multiple cancers including ovarian cancer.
In a recent Phase 2 trial where ENMD-2076 was administered to
platinum-resistant recurrent ovarian cancer patients, some OCCC
patients had prolonged disease control, suggesting that it may be
effective in this subset of patients. We want to explore this further.
The purpose of this study is to examine the response and PFS rates of
ENMD-2076 in this difficult to treat patient population. We look
forward to working closely with EntreMed and colleagues from other
sites in this Phase 2 trial."
Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer commented, "We
are very pleased to have Dr. Oza lead this trial. Dr. Oza was a
principal investigator in our Phase 2 study in platinum resistant
ovarian cancer and has been instrumental in advancing our development
program targeting this indication. The cumulative evidence has
indicated the potential effectiveness of a combined anti-angiogenic
and anti-Aurora A targeted approach in OCCC, and we believe ENMD-2076
presents strong clinical and scientific rationale for the treatment of
this subset of patient population. This trial will provide us with
more insight into the drug's clinical activities and its correlation
with biomarkers."
Dr. Ren further commented, "Together with our trials in triple
negative breast cancer and soft tissue sarcoma, this is the third
clinical trial we have initiated for ENMD-2076 under our US/China
development model. We intend to expand the trial into China once we
have it underway in Canada and the US. Our goal is to reach a
clinical inflection point using a cost-effective approach that
combines speed, quality and lower costs, in order to maximize the
value proposition of ENMD-2076. We are confident that we will reach
this goal."
AI
